Back to News
Market Impact: 0.25
Johnson & Johnson's JNJ-6143 Shows Strong Early Efficacy In Pretreated Advanced Prostate Cancer
Source: Nasdaq
Healthcare & Biotech
Johnson & Johnson reported encouraging Phase 1 data for JNJ-6143, an investigational oral therapy for advanced prostate cancer. The company highlighted significant anti-tumor activity among patients previously treated with multiple lines of therapy; no numerical results were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
JNJ0.60
More News
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
- Ex-PepsiCo CEO Indra Nooyi worked from midnight until 5 a.m. as a receptionist to pay for her Yale degree—and she says ‘respect went up’ because of it
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217